G
Genetic Archaeology
GENETIC ARCHAEOLOGY // PROFILE

CHEK2

Checkpoint Kinase 2

CHR 22
22q12.1

Overview

The CHEK2 gene (Checkpoint Kinase 2) acts as the DNA emergency dispatcher inside the cell nucleus. Whenever ionizing radiation or replication stress creates double-strand DNA breaks, ATM activates CHEK2, which immediately relays “stop dividing” orders to TP53 and BRCA1 until repair finishes cleanly.

Unlike high-penetrance genes such as BRCA1 and BRCA2, CHEK2 is classified clinically as a moderate-penetrance susceptibility gene—meaning enhanced screening (such as earlier breast MRI/mammography) is standardly favored over drastic prophylactic surgery in most cases.

📍 Position
22q12.1 (Chromosome 22)
🏷️ Category
Tumor Suppressor & Oncology
🧪 Function
DNA Damage Checkpoint Kinase
📊 Influence
Moderate breast & prostate risk

Function of CHEK2

Because risk modifies strongly alongside overall family history and polygenic scores, clinical risk calculators combine CHEK2 status (for instance c.1100delC vs. much milder Ile157Thr) with close-relative cancer history before tailoring surveillance age.

Key Aspects:

🎗️ Moderate Risk (c.1100delC)

Carrying one c.1100delC frameshift copy raises female lifetime breast cancer probability to roughly 20–30% (higher if close relatives were affected), prompting intensified annual MRI/mammography starting around age 40.

👨 Prostate & Colorectal Context

Men carrying pathogenic CHEK2 variants benefit from discussing earlier PSA baseline checks around age 40–45 with urology specialists.

💡 Clear Distinction Between Variants: Truncating c.1100delC (~2.5x odds) and common missense Ile157Thr (~1.4x odds) carry very different clinical weight—always verify exact variant pathogenicity with a genetics specialist.

🧬 Genetic Variants (SNPs)

Two founder CHEK2 variants widely present in Northern and Central European clinical panels:

rs555607708
22:28695868
Normal

G
/
Truncating

delC
CHEK2 c.1100delC
Creates a premature stop codon abolishing kinase activity; moderate-risk clinical actionability marker per NCCN breast/prostate guidelines.
Population frequency:
~0.5-1% (N/C Europe)
rs17879961
22:28725099
Ile157

A
/
Thr157

G
CHEK2 Ile157Thr
Low-penetrance missense change (~1.4x odds ratio) generally managed via individualized family-history risk assessment rather than aggressive intervention.
G allele frequency:
~2-5% (C/E Europe)

Practical Significance

✅ Strategies & Guidance

  • Individualized Risk Calculation: Request validated multifactorial modeling (CanRisk / BOADICEA) integrating CHEK2 status plus family pedigree.
  • Intensified Early Detection: Pathogenic CHEK2 carriers typically begin annual screening MRI/mammography earlier (around age 40 or per NCCN).
  • Support General Cancer Prevention: Moderate alcohol minimization, post-menopausal healthy weight, and brisk weekly aerobic activity measurably trim breast cancer risk.

⚠️ Clinical Notes & Risks

  • Contralateral & Multi-Organ Notes: Biallelic homozygotes (very rare, two c.1100delC copies) carry markedly higher multi-cancer susceptibility.
  • False Positives on Consumer Chips: Consumer array calls for rare indels like c.1100delC exhibit notorious false-positive rates—always confirm via accredited clinical sequencing.
  • BRCA Confusion: Do not mistake moderate CHEK2 management protocols for high-penetrance BRCA1/2 protocols.
🩺 Medical Disclaimer: Genetic test results for CHEK2 (Checkpoint Kinase 2) should always be interpreted alongside laboratory biomarkers, medications, and qualified medical or genetic counseling.

📚 Data Sources

  • OMIM: #604373 (Checkpoint Kinase 2)
  • dbSNP & ClinVar: rs555607708 (c.1100delC), rs17879961 (Ile157Thr)
  • NCCN Clinical Practice Guidelines: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic

Last Update: November 2026

Related Research Guides for CHEK2

Related Genes in Tumor Suppressor